Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease

Trial Profile

Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; Expanded access
  • Sponsors Takeda
  • Most Recent Events

    • 09 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 08 Dec 2016 Planned initiation date changed from 1 Nov 2016 to 1 Aug 2016.
    • 15 Nov 2016 Planned initiation date changed from 1 Aug 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top